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Genetic Testing: Balancing Preventative
Medicine with Privacy and Nondiscrimination
JONATHAN Hsu *
Abstract: Genetic testing promises to provide patients with
substantial benefits through early diagnosis, preventative
medicine, and individualized treatments. It also promises to
reduce the overall societal cost of healthcare. Yet, use of
genetic testing also poses significant privacy and
discrimination concerns, particularly in the context of
health insurance coverage. Current legislation and
regulatory schemes do not effectively balance these
competing interests. This Note examines these
shortcomings, and suggests that future legislative and
regulatory efforts should not impose a single standard on
all genetic tests. Rather, permitted uses of genetic test
results by insurers should depend on the statistical
predictive value of the particular test at issue.
I. INTRODUCTION
Current state and federal legislative schemes regulate genetic
information much in the same way the Health Insurance Portability
and Accountability Act ("HIPAA") regulates other individually
identifiable health information-by simply limiting the disclosure and
use of certain categories of information. This approach is ineffective
because genetic testing is more complex than other medical tests that
generate individually identifiable health information. With genetic
tests, statistical confidence levels vary greatly from test-to-test, and
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some genetic tests therefore pose a significantly greater risk of
inaccurate results than others. Inaccurate information about risk for
disease could unfairly affect an individual's insurance coverage, while
accurate information could improve care and reduce costs through
effective preventative medicine and early detection. Balancing these
interests will therefore require future genetic privacy and
nondiscrimination legislation to go beyond the traditional HIPAA
approach to health information regulation, and acknowledge the
differences between the types of tests generating the information in
addition to placing limitations on the information's disclosure and
use.
This Note first addresses the deceptively simple question, "what is
genetic testing?" Most are familiar with genetic fingerprinting (as seen
on the television show "CSI"), and might even be familiar with early
genetic tests such as the test for Huntington's disease. However,
genetic testing has become a vastly more complex industry. Today,
genetic tests claim to reveal everything from a patient's risk for cancer
to the likelihood he or she will respond to a particular drug.
The next part of this Note discusses the various concerns over the
use of genetic information. Popular fear of genetic testing stems from
concerns that doctors and scientists lack a thorough understanding of
genetics and that inaccurate information could be used to
discriminate. It also stems, significantly, from an almost metaphysical
sense of identity that many individuals attach to their genetic code.
The third and fourth parts of this Note outline the current legal
landscape of genetic privacy and nondiscrimination and its
shortcomings. Of the various shortcomings, the most fundamental is
that the current genetic privacy and nondiscrimination laws do not
take into account the wide variety of genetic tests, and thus do not
address significant differences in statistical reliability.
Finally, this Note proposes three principles that should guide
future legislative efforts. First, genetic tests sold directly to consumers
should fall within the HIPAA privacy rule. Second, permitted uses of
genetic test results by insurers should depend on whether the test has
been approved by the FDA. And third, elevated protection of genetic
information due to its association with individual identity should
remain within the realm of state property law.
II. WHAT IS "GENETIC TESTING?"
Like many aspects of medicine and biotechnology, the meaning of
the phrase "genetic testing" has changed dramatically over the last
several years. Most people are familiar with some basic forms of
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genetic testing. Forensic scientists and prosecutors, for example, have
used DNA fingerprinting to identify and convict defendants in
criminal cases in the United States since 1987.' However, in recent
years, genetic testing has advanced at a remarkable rate. At least in
theory, scientists and doctors can now use genetic tests to conduct
clinical diagnoses, evaluate a patient's likely response to a particular
drug, and even predict an individual's risk for future disease.2 As this
part explains, these different types of tests often function in vastly
different ways. This leads to great disparity in statistical confidence
from test-to-test, and helps explain, in part, why genetic privacy and
nondiscrimination legislation has been largely ineffective thus far.
This part examines the three broad categories into which the vast
majority of modern genetic tests fall: (i) diagnostic, (2) non-
diagnostic, and (3) pharmacogenomic.
A. DIAGNOSTIC GENETIC TESTING
Widespread "genetic testing" for the purpose of clinical diagnosis
began in 1963 when Dr. Robert Guthrie developed a test to screen
newborns for phenylketonuria ("PKU").3 PKU is a genetic disorder
caused by a mutation to the PAH gene.4 The PAH gene codes for the
production of the enzyme phenylalanine hydroxylase, which
metabolizes (i.e., breaks down) phenylalanine present in an
individual's diet.s Mutations to the PAH gene severely reduce the
activity of the enzyme phenylalanine hydroxylase, without which
phenylalanine levels build up to toxic levels in the blood and other
tissues of PKU patients. 6 The Guthrie test screened for elevated
1 Michelle Hibbert, DNA Databanks: Law Enforcement's Greatest Surveillance Tool?, 34
WAKE FOREST L. REV. 767, 773 (1999) (noting that in 1987, Tommie Lee Andrews became
the first American to be convicted in a case that utilized DNA evidence).
2 The Universe of Genetic Testing,
http://www.labtestsonline.org/understanding/features/genetics.html (last visited Apr.17,
2011).
3 Genetic Testing Report - Appendix 5, http://www.genome.gov/10002397 (last visited
Apr. 17, 2011).
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phenylalanine levels to detect the disease, but did not directly detect
mutations in the patients' PAH gene sequence.:
After the initial success of the Guthrie test for PKU, other success
stories followed. Scientists soon developed tests for the diagnosis of
sickle cell disease and Tay-Sachs disease. As with PKU, mutations to
single genes cause sickle cell disease and Tay-Sachs disease.8 And like
the Guthrie test for PKU, these tests detected abnormalities in each
gene's metabolites (i.e., the enzymes and proteins the gene codes for)
rather than mutations in the genetic sequence itself.9 The genetic test
developed to confirm the presence of Huntington's disease did test for
a particular genetic sequence as opposed to the protein for which the
sequence codes.lo But again, as with the other diseases subject to early
genetic diagnostic tests, a mutation to a single gene causes
Huntington's disease.",
However, scientists soon discovered that unlike PKU, sickle cell
disease, Tay-Sachs disease, and Huntington's disease, the vast
majority of genetic diseases bear "gene signatures" consisting of
numerous genes.12 Further, they discovered that mutations to these
genes most often operate merely to increase one's risk for a disease or
7 Robert Guthrie & Ada Susi, A Simple Phenylalanine Method for Detecting
Phenylketonuria in Large Populations ofNewborn Infants, 32 PEDIATRICS 338, 342
(1963).
8 Sickle cell disease, http://ghr.nlm.nih.gov/condition=sicklecelldisease (last visited Apr.
17, 2011) (Sickle Cell Anemia is caused by mutations to the HBB gene); Tay-Sachs disease,
http://ghr.nlm.nih.gov/condition=taysachsdisease (last visited Apr. 17, 2011) (Tay-Sachs
disease is caused by mutations to the HEXA gene).
9 Sickle Cell Test, http://www.nlm.nih.gov/medlineplus/ency/article/oo3666.htm (last
visited Apr. 17, 2011) (A sickle cell test looks for the presence or absence of abnormal
hemoglobin in the blood that causes sickle cell anemia); Tay-Sachs Disease,
http://www.nlm.nih.gov/medlineplus/ency/article/ool417.htm (last visited Apr. 17, 2011)
(Additional tests may include ... Enzyme analysis of blood or body tissue for
hexosaminidase levels).
10 Learning About Huntington's Disease, http://www.genome.gov/1ooo1215 (last visited
Apr. 17, 2011).
1 Id.
12 See SNPs: Variations on a Theme,
http://www.ncbi.nlm.nih.gov/About/primer/snps.html (last visited Apr. 17, 2011) (Many
common diseases in humans are not caused by a genetic variation within a single gene but
are influenced by complex interacfions among multiple genes as well as environmental and
lifestyle factors).
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disorder rather than to conclusively cause it.13 iWhle a large
proportion of recent genetic research therefore focuses on risk
assessment as opposed to clinical diagnosis, some genetic
predisposition for disease is nonetheless so great that the
predisposition is itself considered a disease,14 warranting prophylactic
measures by the patient.'5
Tests for severe genetic predisposition would fall within the Food
& Drug Administration's ("FDA") definition of in vitro diagnostics
tests (subjecting them to FDA regulation) due to the prophylactic
measures doctors may recommend as a result of the patient's
diagnosis of a severe genetic predisposition for the disease.16 However,
most such tests are "laboratory developed tests" ("LDTs"),17 over
which the FDA has traditionally declined to exercise regulatory
authority. The LDT exemption-also known as the "home brew" or
"in-house" exemption-allows for the sale of diagnostic tests that are
both manufactured and performed by the same laboratory with
generally little FDA regulation.' 8 While the FDA has jurisdiction over
LDTs,19 it has traditionally regulated only those LDTs that use "analyte
specific reagents" ("ASRs") under its in vitro diagnostic device
regulatory scheme.20 Further, only LDTs that use Class II or Class III
13 Id.
14 See Katskee v. Blue Cross/Blue Shield of Nebraska, 515 N.W.2d 645, 653 (Neb. 1994)
(characterizing breast-ovarian carcinoma syndrome as an illness because patients
diagnosed with the syndrome have at least a 50 percent chance of developing breast and/or
ovarian cancer).
"sGenetic Basis of Cancer Syndromes,
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=cmed6&part=A4561 (last visited
Apr. 17, 2011).
16See 21 C.F.R. § 809.3(a) ("In vitro diagnostic products are those reagents, instruments,
and systems intended for use in the diagnosis of disease or other conditions, including a
determination of the state of health, in order to cure, mitigate, treat, or prevent disease or
its sequelae.").
17 See Genetic Testing, http://www.genome.gov/1o002335 (last visited Apr. 17, 2011).
18Id. (... [T]he FDA does not regulate "home brew" tests, that is, tests that are both
manufactured and performed by the same laboratory.").
19 See Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific
Reagents, 62 Fed. Reg. 62243, 62249 (Nov. 21, 1997) (codified at 21 C.F.R. Parts 809 and
864).
2
0OFOOD & DRUG ADMIN., IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAYS (July 26,
2007), at 7-8, available at
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ASRs21 require pre-market approval or clearance.22 Few genetic tests
fall within this category. 23 Notably, the BRCA1/BRCA2 testing for the
predisposition to breast cancer falls within the LDT exemption, as
Myriad Genetics in Salt Lake City, Utah analyzes all test samples.24
Despite the fact that the majority of tests do not require pre-
market approval or clearance, several companies marketing modern,
sophisticated genetic tests have nonetheless sought and obtained FDA
approval. Most notably, Agendia voluntarily sought FDA approval for
MammaPrint and obtained it in 2007.25 MammaPnnt uses microarray
technology to detect abnormal expression levels in a group of seventy
genes to aid in the evaluation of a breast cancer patient's risk for
metastasis and tumor recurrence.26 Different types of breast cancer
respond to treatments differently, and optimal treatment may vary
depending on a patient's risk for metastasis and tumor recurrence.2 7
According to Agendia, MammaPrint aids doctors in evaluating a
patient's risk, and thus aids them in tailoring that patient's treatment
to her needs.28
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidance
Documents/UCM071455.pdf (last visited Apr. 17, 2011).
21 21 C.F.R. § 864-4020.
22 FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY AND FDA STAFF COMMERCIALLY
DISTRIBUTED ANALYTE SPECIFIC REAGENTS (ASRs): FREQUENTLY ASKED QUESTIONS (Sept.
14, 2007), at 6, available at
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidance
Documents/UCMo71269.pdf (last visited Apr. 17, 2011).
23 See Dan Vorhaus, Personal Genomics Follows Pathway to Corner Drugstore; Is
Regulation Next?, Genomics Law Report, (May 11, 2011), available at
http://www.genomicslawreport.com/index.php/2010/05/11/pathway-walgreens-and-dtc-
regulation/ (last visited Apr. 17, 2011) ("Most ASRs are Class I devices ...").
24 Genetic Testing, supra note 17.
25 Press Release, U.S. Food & Drug Admin., FDA Clears Breast Cancer Specific Molecular
Prognostic Test (Feb. 6, 2007), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucmlo8836.ht
m (last visited Apr. 21, 2011).
26 What You Need to Know about Breast Cancer Recurrence,





Nor has FDA approval been limited to tests that characterize the
risk of recurrence in patients with a known disease. In 2008, the FDA
approved Pathwork Tissue of Origin, a truly diagnostic test in the
sense that it identifies the presence of disease whose origin and
presence might otherwise be unknown.29 The test uses microarray
technology to analyze 1,550 gene expression levels to determine the
origin of metastatic cancer.30 Some cancer patients are not diagnosed
with cancer until it has metastasized and led to symptoms. 31 For these
patients, Pathwork Tissue of Origin can play an important role in their
care by diagnosing the primary cancer (i.e. where the cancer began
before spreading throughout the body) and allowing doctors to tailor
treatment to that type of cancer. 32
Recently, one company has begun to use microarray technology
not to test for genetically complex diseases such as cancer (as in
MammaPrint and Pathwork Tissue of Origin), but rather to test for
numerous diseases caused by mutations to single genes. 33 The test,
known as the Universal Genetic Test, offered by Counsyl, claims to
enable prospective parents to test whether they are carriers for over
loo genetic disorders caused by single genes, including PKU, sickle
cell and Tay-Sachs.34 Although prospective parents have tested for
many of these diseases for several decades, Counsyl differs from
previous screening tests in that it is purportedly able to detect over
loo disorders from a single saliva sample.35 Like the BRCA1/BRCA2
test, Counsyl has thus far escaped FDA regulation under the in-house
29 Press Release, U.S. Food & Drug Admin., FDA Clears Test that Helps Identify Type of
Cancer in Tumor Sample (July 31, 2008), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2oo8/ucmll6931.ht
m (last visited Apr. 17, 2011).
30 Federico Monzon et al., Multicenter Validation of a 1,55o-Gene Expression Profile for
Identification of Tumor Tissue of Origin, 27 J. CLIN. ONCOL. 2503, 2503 (2009).
31 Metastatic Cancer: Q&A, http://www.cancer.gov/cancertopics/factsheet/Sites-
Types/metastatic (last visited Apr. 17, 2011).
32 See id. ("The choice of treatment generally depends on the type of primary cancer
[among other things] ...").
33 See Counsyl, https://www.counsyl.com/ (last visited Apr. 17, 2011); See also Andrew
Pollack, Firm Brings Gene Tests to Masses, N.Y. TIMES, Jan. 29, 2010, at B1.
34 Pollack, supra note 33; See also Preventable Genetic Diseases Covered by the Universal
Genetic Test, https://www.counsyl.com/diseases/ (last visited Apr. 17, 2011).
3s Pollack, supra note 33.
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exception36 despite explicit claims that its test will allow prospective
parents to take preventative measures and engage in more effective
treatment.37
B. NON-DIAGNOSTIC GENETIC TESTING
As noted above, a diagnostic test is designed both to identify a
condition and to influence the patient's subsequent medical
treatment.38 While the best known genetic tests are diagnostic in
nature, an increasing number of companies now market genetic tests
whose stated goal is simply to inform individuals of their genetic risks
without necessarily influencing decisions about their medical care.
Such tests are distinguished from diagnostic tests not only by their
purpose, but also in that they are typically requested without
physician consultation.39
Although numerous companies offer non-diagnostic genetic tests,
deCODE Genetics and 23andMe (a Google-backed company) remain
the most well-known. Both companies market genetic tests that claim
to inform customers about their genetic risks for numerous diseases.4o
deCODE and 23andMe sell their tests online, shipping customers a
sample collection kit.4' Customers then either swab the inside of their
cheek (as with deCODE) or spit into a test tube (as with 23andMe)
36 See Pollack, supra note 33.
37 Early Testing Allows Prevention, https://www.counsyl.com/learn/prevent-genetic-
disease/ (last visited Apr. 17, 2011).
38 21 C.F.R. § 809.3(a).
39 See Jennifer A. Gniady, Note, Regulating Direct-to-Consumer Genetic Testing:
Protecting the Consumer Without Quashing a Medical Revolution, 76 FORDHAM L. REV.
2429, 2241-42 (2008) (noting that "diagnostic tests ... are ... more likely to involve a
physician or genetic counselor in the course of administering and interpreting the results
of the test.").
40 See e.g., Genetic Risk for 47 Conditions in One Scan,
http://www.decodeme.com/conditions-covered (last visited Apr. 17, 2011) (listing
conditions covered by deCODE's whole genome scan); See also List of Conditions,
https://WWW.23andme.com/health/all/ (last visited Apr. 17, 2011) (listing conditions
covered by 23andMe's scan).
41 See About deCODEme, http://www.decodeme.com/about-decodeme (last visited Apr.
17, 2011); See also Using Your Personal DNA Test,
https://www.23andme.com/howitworks/ (last visited Apr. 17, 2011).
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and ship their sample back to the laboratory for analysis.42 Both the
deCODE and 23andMe laboratories then use microarrays to analyze
the samples for various single nucleotide polymorphisms ("SNPs")
that are associated with the conditions covered by their respective
scans. 43 Finally, the companies give customers access to a report
detailing the SNPs revealed by the laboratory analysis and explaining
what the presence of those SNPs might mean for the individual's risk
for disease.44 While these companies claim to offer insight into an
individual's genetic risk for various diseases, they are careful to
characterize the tests as non-diagnostic in nature.45
As with diagnostic genetic tests, the vast majority of non-
diagnostic genetic tests have not traditionally required pre-market
FDA approval due to the LDT (in-house) exemption. However, as
Direct-to-Consumer ("DTC") genetic tests have become increasingly
available to consumers, the FDA has begun to rethink its position on
LDTs.46 In 2007, the FDA issued proposed draft guidance that would
require pre-market approval or clearance for "in vitro diagnostic
multivariate index assays," which seek to analyze multiple variables
(i.e., multiple genes) to yield a "score"9 or "index" characterizing a
particular patient's risk.47 Then in May 2010, when Walgreens
42 Id.
43 See SNP Measurement and Risk Calculation, http://demo.decodeme.com/health-
watch/snp-measurement (last visited Apr. 17, 2011) (Illumina's bead chip is a type of
microarray); See also Our Service: Genotyping Technology,
https://WWW.23andme.com/more/genotyping/ (last visited Apr. 17, 2011).
44 See e.g., Try deCODEme using the Demo User Account,
http://demo.decodeme.com/your-results (last visited Apr. 17, 2011).
45 See e.g., Frequently Asked Questions, http://www.decodeme.com/faq#interpreting3
(last visited Apr. 17, 2011) ("deCODEme provides information about your genetic risk. It
does not make a definitive diagnosis..."); See also Why Can't 23andMe Diagnose Me?,
https://www.23andme.com/you/faqwin/nodiagnosis/ (last visited Apr. 17, 2011)
("23andMe provides you with genetic information, but does not sequence your entire
genome or perform predictive or diagnostic tests.").
46 Rob Stein, Walgreens Won't Sell Over-the-Counter Genetic Test After FDA Raises
Questions, WASH. POST, May 13, 20o, at Ao2; Press release, FDA to Host Public Meeting
on Oversight of Laboratory-Developed Tests (June 16, 2010), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm215766.htm (last
visited Apr. 17, 2011).
47 FOOD & DRUG ADMIN., supra note 20, at 7-8 ("Class II medical devices typically require
FDA clearance ... Class III devices require the submission of an application for Premarket
Approval ... we believe most IVMLAs will be either class II or III devices ... ").
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announced its intention to sell Pathway Genomics' test kit at its stores,
the FDA issued a letter stating its belief that the test kit required
approval.48 One month later, the FDA followed with similar letters to
23andMe, Navigenics, deCODE, Illumina and Knome.49 And in July
2010, the FDA held a public meeting to discuss potential changes to
the way it oversees LTDs.5o
C. PHARMACOGENOMICS/ PHARMACOGENETICS
"Pharmacogenomics" and "pharmacogenetics" are essentially
interchangeable terms, which the National Center for Biotechnology
Information ("NCBI") defines as the "science that examines the
inherited variations in genes that dictate drug response and explores
the ways these variations can be used to predict whether a patient will
have a good response to a drug, a bad response to a drug, or no
response at all."s' Rather than using genetics to diagnose, cure or
48 Letter from James Woods, Deputy Director, Food and Drug Administration, to James
Plante, Founder and CEO, Pathway Genomics Corporation (May 10, 201o), available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM211875.
pdf (last visited Apr. 17, 2011).
49 Letter from Alberto Gutierrez, Food and Drug Administration, to Anne Wojcicki,
President and Co-Founder, 23andMe, Inc. (June 10, 2010), available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM215240.
pdf (last visited Apr. 17, 2011); Letter from Alberto Gutierrez, Food and Drug
Administration, to Vance Vanier, President and CEO, Navigenics (June 10, 2010),
available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM215243.
pdf (last visited Apr. 17, 2011); Letter from Alberto Gutierrez, Food and Drug
Administration, to Earl M. Collier, Jr., CEO, deCODE Genetics (June 10, 2010),
available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM215241.
pdf (last visited Apr. 17, 2011); Letter from Alberto Gutierrez, Food and Drug
Administration, to Jay T. Flatley, President and CEO, Illumina, Inc. (June 10, 2010),
available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM215242.
pdf (last visited Apr. 17, 2011); Letter from Alberto Gutierrez, Food and Drug
Administration, to Jorge Conde, Co-Founder and CEO, Knome, Inc. (June 10, 2010),
available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM215239.
pdf (last visited Apr. 17, 2011).
50 Press release, FDA to Host Public Meeting on Oversight of Laboratory-Developed Tests,
supra note 46.
5' Pharmacogenomics Fact Sheet,
http://www.ncbi.nlm.nih.gov/About/primer/pharm.html (last visited Apr. 17, 2011).
prevent disease, pharmacogenomics seeks to use genetics to explain
"the great heterogeneity in the way individuals respond to medication,
in terms of both host toxicity and treatment efficacy."52 A
pharmacogenomic genetic test, then, seeks to determine a patient's
genotype to aid doctors in selecting an appropriate drug or an
appropriate drug dosage.53 The FDA has approved only a limited
number of pharmacogenomic tests, with two notable examples being
Roche's Amplichip and DAKO's HercepTest.
Amplichip, like several of the tests discussed above, uses
microarray technology to detect mutations in the genes CYP2C19 and
CYP2D6.54 These genes affect the metabolism of a wide variety of
drugs, including antipsychotics, antidepressants, P-blockers, anti-
arrhythmic agents and opiates.55 By evaluating a patient's CYP2C19
and CYP2D6 gene expression levels, AmpliChip purports to allow
doctors to better tailor treatment to an individual patient.56
DAKO's HercepTest uses an immunohistochemical assay to test
for HER2 over-expression.57 The HER2 gene codes for a membrane
receptor protein associated with cell growth and proliferation.s8 Over-
expression of the HER2 gene creates extra HER2 proteins within the
cell membrane, leading to excessive cell growth and/or proliferation.59
HercepTest tests for HER2 over-expression by binding staining agents
52 William Evans and Mary Relling, Pharmacogenomics: Translating Functional Genomics
into Rational Therapeutics, 286 SCIENCE 487,487 (1999).
53 Id. at 490-91 ("...automated systems are being developed to determine an individual's
genotype for polymorphic genes that are known to be involved in the pathogenesis of their
disease, in the metabolism and disposition of medications, and in the targets of drug
therapy. Such diagnostics, which need be performed only once for each battery of genes
tested, can then become the blueprint for individualizing drug therapy.").
s4AmpliChip CYP45o Test, http://www.roche.com/products/product-
details.htmtype=product&id=17 (last visited Apr. 17, 2011).
55 L. DiAnne Bradford, CYP2D6 Allele Frequency in European Caucasians, Asians,
Africans and Their Descendants, 3 PHARMACOGENOMICS 229, 229 (2002).
s6AmpliChip CYP45o Test, supra note 54.
57 HercepTestlm Interpretation Manual, available at
http://www.dako.com/us/index/knowledgecenter/kc-publications/kc-publicationsinter
pret/herceptest.htm (last visited Apr. 17, 2011), at 3.
58 Id. at 5.
59 Id.
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to HER2 proteins, allowing the user to evaluate the expression level of
HER2 based on an imaging analysis of the stained tumor tissue.60 The
drug Herceptin works by blocking HER2 protein activity, and is thus
thought to be effective only in patients whose cancer is related to
HER2 over-expression.61 Doctors can therefore use HercepTest as an
aid in determining which patients are likely to benefit from Herceptin
use.6 2
As noted above, however, FDA-approved pharmacogenomic tests
such as Amplichip and HercepTest remain the exception rather than
the rule. As with diagnostic genetic testing, a majority of
pharmacogenomic test vendors have taken advantage of the "in-
house" exemption and have escaped nearly all FDA regulation. For
example, Ziagen (an antiretroviral medication used in the treatment of
HIV, also known as Abacavir) produces a serious adverse event
("SAE") in approximately 5% of patients. 63 An allele (i.e., discrete
genetic variant) of the major histocompatability complex ("MHC")
known as HLA-B*5701 is thought to be associated with these Ziagen-
induced SAEs.64 A number of laboratories, including LabCorp, now
offer an "in-house" pharmacogenetic screening test for the HLA-
B*5701 to aid in determining which patients might be likely to have an
SAE as a result of taking Ziagen. 65
A similar example is found in association with the drug Tegretol,
an anticonvulsant and specific analgesic for the treatment of
6o Id. at 7.
6i See Herceptin Package Insert, available at
http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf (last
visited Apr. 17, 2011), at 6.
62 HercepTest Interpretation Manual, supra note 57, at 3.
63 Simon Mallal et al., Association Between Presence ofHLA-B*57ol, HLA-DR7, and HLA-
DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir, 359
LANCET 727, 727 (2002).
64 Id.
65 Malorye Allison, Is Personalized Medicine Finally Arriving?, 26 NAT. BIOTECHNOL. 509,
514 (2008); Ziagen Package Insert, available at
http://us.gsk.com/products/assets/us-ziagen.pdf (last visited Apr. 17, 2011), at 2; HLA-
B*5701 Genotyping, available at
https://www.1abcorp.com/.EdosPortet/TestMenuLibray?libName= File+Library&compN
ame= L1148 (last visited Apr. 17, 2011).
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trigeminal neuralgia. 66 The MHC allele HLA-B*1502 appears to be
associated with Tegretol-induced SAEs, at least among Asians. 67 As
with Ziagen, several vendors now offer "in-house" pharmacogenetic
screening tests for the HLA-B*1502 allele to aid in determining a
patient's likelihood of experiencing a Tegretol-induced SAE. 68
III. GENETIC TESTING, PRIVACY AND DISCRIMINATION
Fear of genetic testing is not new. In part, it stems from a long and
tragic history of its misunderstanding and misuse. The infamous Nazi
physician Josef Mengele engaged in extensive and brutal genetic
experimentation for the purpose of "proving" the superiority of the
Aryan race.69 Even the United States once embraced eugenics and
forced sterilization programs.70 In his now-infamous opinion in Buck
v. Bell, Justice Holmes declared that it was desirable to "prevent those
who are manifestly unfit from continuing their kind."71 The Supreme
Court held that the forced sterilization of a mentally retarded woman,
whose mother and grandmother were also believed to be mentally
retarded, was not a violation of her Constitutional rights.72 If genetic
science has led us to take such extreme missteps in the past, how are
we to know that it will not happen again? It is true that scientists in
the early to mid-twentieth century understood much less about
genetics than they do today, but our understanding of genetics today
is still largely incomplete.
66 Tegretol Package Insert, available at
http://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (last visited Apr. 17,
2011), at 2.
67Kheng Seang Lim et al., Association of HLA-B*15o2 Allele and Carbamazepine Induced
Severe Adverse Cutaneous Drug Reaction Among Asians, a Review, 13 NEUROL. ASIA 15,
15 (2oo8); See also Tegretol Package Insert, supra note 66, at 1.
68 See, e.g., https://www.labcorp.com/wps/portal/provider/testmenu (search "167359")
(last visited Apr. 17, 2011).
69 JUDITH T. BAUMEL, THE HOLOCAUST ENCYCLOPEDIA 412 (Walter Laqueur ed., Yale Univ.
Press, 1st ed. 2001).
70See Buck v. Bell, 274 U.S. 200, 47 S. Ct. 584 (1927).
71 Id. at 207.
72 Id. at 208.
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It is also not only the application of genetic science and technology
to humans that creates fear. The 1990s and early 2000s saw an
intense backlash against so-called "frankenfood" (i.e., genetically
engineered food).73 Although the use of recombinant DNA technology
in crop development did not fundamentally differ from what plant
breeders and farmers had practiced for millennia through selective
breeding, many nonetheless perceived it as unfamiliar and
unnatural.74 This unfamiliarity-based fear is likewise not a new
phenomenon.7s Although in some ways, genetic engineering was
actually more precise and predictable than traditional selection
techniques because of its ability to introduce a single new gene at a
time,76 many people still perceived genetically engineered foods as less
safe than foods produced using more traditional techniques.7?
Thus, our concern over genetic privacy and nondiscrimination
stems from two distinct sources. First, it stems from a concern that
scientists' and doctors' understanding of genetic science is incomplete.
And second, it stems from a concern that as a society, we lack
sufficient safeguards to prevent the discriminatory use of genetic
information, whether flawed or not.
These concerns manifest themselves in a number of scenarios. For
example, perhaps an employer could test prospective employees and
reject those likely to develop a complex-and expensive to treat-
disease. Or perhaps a prospective spouse could test his or her partner
to evaluate the other's "genetic potential" before committing to
marriage. Yet, the most pressing genetic privacy and
nondiscrimination anxiety for the typical individual (and the subject
of this note) occurs in the context of applying genetic testing to health
insurance.78
73 See Henry I. Miller & Gregory Conko, The Frankenfood Myth: How Protest and Politics
Threaten the Biotech Revolution (Praeger Publishers 2004).
74 Id. at 19, 22.
75 Id. at 27 ("There is a cartoon that depicts prehistoric cave dwellers gathered around a
campfire, when a lookout peering into the distance shouts a warning: 'Quick, put it out;
here comes the anti-fire activists!'").
76 Id. at 6.
77Id. at 19.
78 NANCY LEE JONES AND AMANDA K. SARATA, GENETIC INFORMATION: LEGAL ISSUES
RELATING TO DISCRIMINATION AND PRIVACY 4 (Comm. Print 2008).
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Insurance companies have long set premiums on the basis of
statistical risk (though, as discussed in greater detail below, this will
change beginning in 2014), and they argue that the use of genetic
information is important because it allows them to more accurately
assess a policy holder's risk and more accurately set premiums.79
Further, such information is also potentially of extreme importance to
policy holders themselves because prophylactic or preventative
measures may be available upon discovering one's genetic
predisposition to a particular disease,so and because
pharmacogenomic testing may allow doctors to choose a treatment or
determine a dosage more effectively. 8 ' And for society as a whole, such
preventative measures and personalized medicine may also be a
means to significantly reducing overall health care costs.8 2
Yet, in spite of these potential benefits, most individuals feel some
level of discomfort in giving their insurers (or employers) full access to
their genetic information. For example, when one employer began to
discuss implementing a genetic screening test to identify workers
likely to contract chronic beryllium disease, union officials vehemently
expressed their displeasure.83 They argued that employees would be
unable to obtain health insurance and would be discriminated against
by other employers in the future. 84 Prior to the passage of health care
reform laws in 2010, a report compiled for Congress also found that
"68 percent agree that insurers would do everything possible to use
genetic information to deny health coverage."8 s Individual cases
asserting actual discrimination on the basis of genetic testing are rare,
79 Elaine Draper, The Screening of America: The Social and Legal Framework of
Employers' Use of Genetic Information, 20 BERKLEY J. EMP. & LAB. L. 286, 289 (1999).
8o See Genetic Basis of Cancer Syndromes, supra note 15; See also Kasparian et al., Genetic
Testing for Melanoma Risk: A Prospective Cohort Study of Uptake and Outcomes Among
Australian Families, 11 GENETICS IN MEDICINE 265 (2009) (observing that those identified
as having higher risk for melanoma engaged in more frequent clinical skin examinations).
11 See Evans & Relling, supra note 52.
82 Monte Malach & W.J. Baumol, Opportunities for the Cost Reduction of Medical Care, 34
J. COMMUNITY HEALTH 255, 255 (2009).
83 Diane Lewis, Under a Genetic Cloud: The Benefits of DNA Testing Come with a
Potentialfor Abuse, THE BOSTON GLOBE, Aug. 14, 1994, at Al.
84 Id.
85 Jones & Sarata, supra note 78, at 4.
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but the Council for Responsible Genetics does cite some examples,
including a healthy seven-year-old child who was denied health
insurance coverage because genetic tests claimed to reveal a
predisposition for heart disease.86
Concern over insurer use of genetic information generally falls
into four categories. First, there is a fear that insurers could use
genetic information to discriminate unfairly in setting premiums or
denying coverage. The vast majority of genetic disorders are caused by
complex interactions among numerous genes and numerous
environmental factors.87 Thus, an adverse genetic test result may not
reflect an individual's actual risk of developing symptoms requiring
medical treatment. In other words, the concern is that insurers may
not fully understand the true statistical significance of a particular test
result. Further, because genetic traits often fall along ethnic lines,
there is a fear that insurance companies could use genetic information
as a pretext for racial discrimination.
Second, both the law and society generally favor differentiating
individuals on the basis of "lifestyle choices" rather than immutable
characteristics. 88 For example, illegal drug use is generally regarded as
an acceptable basis for differentiation. 89 However, it is now widely
accepted that some individuals are more susceptible to addiction than
others.90 Thus, there is concern that insurers could use genetic testing
to discriminate against those who, for example, have never used illegal
drugs or smoked, but who are nonetheless genetically predisposed to
addiction.
Third, pharmacogenomic tests may reveal that a patient is unlikely
to respond favorably to a particular treatment or may be particularly
likely to have severe side-effects. Therefore, it is possible that
insurance companies will deny some patients coverage for such
treatments. In the context of terminal patients for whom experimental
86 CENTER FOR RESPONSIBLE GENETICS, GENETIC DISCRIMINATION: POSITION PAPER,
available at
http://www.councilforresponsiblegenetics.org/pageDocuments/2RSW5M2HJ2.pdf (last
visited, Apr. 17, 2011).
87 SNPs: Variations on a Theme, supra note 12.
88 Draper, supra note 79, at 306-07.
89 Id.
90 See Peter Kalivas, Predisposition to Addiction: Pharmacokinetics, Pharmacodynamics,
and Brain Circuitry, i6o AM. J. PSYCHIATRY 1, 1 (2003).
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treatments often offer the only hope, there is a concern-and a lively
ongoing debate-about the fairness of such decisions.91
Finally, even beyond concerns over the technology and its
applications, there is the feeling that genetic information is uniquely
personal. One commentator has referred to an individual's genetic
code as a "coded future diary."92 Others have observed that today,
"DNA appears in popular culture as a soul-like entity."93 Walter
Gilbert, who pioneered methods for sequencing DNA, stated that
understanding one's genetic code is "the ultimate answer to the
commandment 'Know thyself."'94 Even those who seek to debunk the
idea of "DNA as soul," and who argue against elevating legal
protections for genetic information beyond that of other health
information, nonetheless acknowledge the existence of such
sensitivities. 95
Thus, legislative and regulatory efforts to control genetic privacy
must balance the interest in cost-reduction and preventative medicine
against the interest in avoiding discriminatory insurance practices.
And as if balancing those interests was not difficult enough, legislators
must also recognize that genetic information can be intensely personal
in a way that other forms of health information generally are not.
IV. THE LEGAL FRAMEWORK OF GENETIC PRIVACY AND
NONDISCRIMINATION
Until recently, federal legislation pertaining explicitly to genetic
information did not exist. Issues of genetic privacy and
nondiscrimination were dealt with only indirectly under HIPAA and
the Americans with Disabilities Act ("ADA"). Part of the American
91 NUFFIELD COUNCIL ON BIOETHICS, PHARMACOGENETICS: ETHICAL ISSUES 6o, available at
http://nuffieldbioethics.org/sites/default/files/Pharmacogenetics%2oReport.pdf.
92 George J. Annas, Privacy Rules for DNA Databanks: Protecting Coded 'Future Diaries,'
270 J. AM. MED. Ass'N, 2346 (1993).
93 Hugh Miller, DNA Blueprints, Personhood, and Genetic Privacy, 8 HEALTH MATRIX 179,
18i, quoting DOROTHY NELKIN & M. SUSAN LINDEE, THE DNA MYSTIQUE: THE GENE AS A
CULTURAL ICON 41 (W. H. Freeman 1995).
94 JERRY E. BISHOP & MICHAEL WALDHOLZ, GENOME: THE STORY OF THE MOST ASTONISHING
SCIENTIFIC ADVENTURE OF OUR TIME 218 (Touchstone Books 1991) (quoting Walter
Gilbert).
95 Miller, supra note 93.
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Recovery and Reinvestment Act ("ARRA") directed the Department of
Health and Human Services ("HHS") and the Federal Trade
Commission ("FTC") to conduct a study on privacy issues pertaining
to vendors of "personal health records" ("PHRs") and related entities
(which arguably includes vendors of genetic tests).96 The ARRA also
required the FTC to issue an interim health breach notification rule.97
Although some groups submitted comments recommending the
inclusion of genetic test vendors under the proposed rule's definition
of PHR vendors,98 the FTC's final notification rule made no mention
of genetic data or genetic test vendors.99 However, in October of 2009,
HHS issued proposed modifications to the HIPAA Privacy Rule
pursuant to the Genetic Information Nondiscrimination Act of 2008
("GINA").o10 These modifications explicitly included genetic
information in the Privacy Rule's definition of "health information"oi
and became the first explicit federal regulations for genetic privacy
and nondiscrimination.
Then, in March 2010, President Obama signed into law the Patient
Protection and Affordable Care Act ("PPACA"). PPACA provided for
sweeping reform of the health care insurance industry. Among its
many provisions, beginning January 1, 2014, PPACA will prohibit
insurers from determining eligibility on the basis of genetic
informationlO2 and will prohibit insurers from charging differential
premium rates except on the basis of family structure, geography,
96 American Recover and Reinvestment Act of 2009, Pub. L. No. 111-5, § 13424, 123 Stat.
277-78 (2009) (codified at 42 U.S.C. § 17953).
97 Id.
98 See, e.g., Letter from Ashley Katz, Coalition for Patient Privacy Rights, to Cora Tung Han
& Maneesha Mithal, Fed. Trade Comm'n, at 3, available at
http://www.ftc.gov/os/comments/healthinfobreach/541358-oo113.pdf (last visited Apr.
17, 2011).
99 Health Breach Notification Rule, 74 Fed. Reg. 42,962 (Aug. 25, 2009) (to be codified at
16 C.F.R pt. 318).
100 HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable
Health Information, 74 Fed. Reg. 51,698, 51,698 (proposed Oct. 7, 2009) (to be codified at
45 C.F.R. pt. 160 & 164).
1o Id. at 51,700.
102 Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, §2705(a), 124
Stat. 156 (2010) (effective Jan. 1, 2014).
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actuarial value, tobacco use, participation in a health promotion
program, and age.103
An increasing number of states have also passed laws addressing
genetic privacy and nondiscrimination. State genetic privacy laws vary
widely in scope. They include provisions that require patient access to
genetic information, that require patient consent in a variety of
scenarios before disclosure, that define genetic information as
personal property, and that provide civil remedies for breaches of
genetic privacy.104 State genetic nondiscrimination laws likewise vary
in scope. Some such laws include provisions that variously prohibit
insurers from using genetic information to establish eligibility and/or
for risk assessment, as well as from requiring policy holders to
undergo genetic testing.1o5
A. FEDERAL LAW
I. AMERICANS WITH DISABILITIES ACT OF 1990
The general rule under the ADA states, "No covered entity shall
discriminate against a qualified individual on the basis of
disability..."io6 However, a "covered entity" is defined only as "an
employer, employment agency, labor organization, or joint labor-
management committee."107 Thus, while there is some debate as to
whether a genetic disorder constitutes a "disability" under the ADA,los
103 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 2701(a), 124
Stat. 155 (2010) (effective Jan. 1, 2014).
104 Genetic Privacy Laws,
http://www.ncsl.org/IssuesResearch/Health/GeneticPrivacyLaws/tabid/14287/Default.as
px (last visited Apr. 17, 2011).
105 Genetic Nondiscrimination in Health Insurance Laws,
http://www.ncsl.org/IssuesResearch/Health/GeneticNondiscriminationinHealthInsuranc
eLaws/tabid/14374/Default.aspx (last visited Apr. 17, 2011).
106 Americans with Disabilities Act of 1990, 42 U.S.C. § 12112(a) (2009) (emphasis added).
'o7Americans with Disabilities Act of 1990, 42 U.S.C. § 12111(2) (2009).
1o8 See Frances Miller & Philip Huvos, Genetic Blueprints, Employer Cost-Cutting, and the
Americans with Disabilities Act, 46 ADMIN. L. REV. 369 (1994); See also EQUAL
EMPLOYMENT OPPORThNITY COMMISSION, SECTION 902 DEFINITION OF THE TERM
DISABILITY (1995), available at http://www.eeoc.gov/policy/docs/9o2cm.html (last visited
Apr. 17, 2011) ("... 'disability' applies to individuals who are subjected to discrimination on
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none of the ADA's provisions apply directly to either insurers or
vendors of genetic tests. Furthermore, the ADA explicitly exempts
insurance risk underwriting from its scope. 09
Nonetheless, the ADA is still somewhat relevant in the context of
health insurance because many employers offer health insurance as an
employment benefit.nlo The ADA's prohibition on disability-based
discrimination by employers does extend to employer-provided health
insurance."' However, the Equal Employment Opportunity
Commission ("EEOC") has stated that a distinction is not "disability-
based discrimination" if "it is a broad distinction which applies to a
multitude of dissimilar conditions" and "it constrains both individuals
with and individuals without disabilities."112 A broad distinction on the
basis of "genetic disorders" would clearly apply to a multitude of
dissimilar conditions. Also, as discussed above, many predispositions
for disease are not themselves considered diseases, and are therefore
likely not "disabilities" under the ADA."3 Even though some genetic
disorders are likely "disabilities" under the ADA, and even though the
ADA prohibits disability-based discrimination in employer-provided
health insurance, it is thus unclear whether using a broad range of
genetic information to underwrite employer-provided health
insurance would violate the ADA.
2. HEALTH INSURANCE PORTABILITY AND
ACCOUNTABILITY ACT OF 1996
HIPAA addresses genetic information in a number of ways. As
applied directly to insurers, it limits the ways in which group health
plans"1 may use genetic information. HIPAA states that "[g]enetic
the basis of genetic information relating to illness, disease, or other disorders....Those
individuals, therefore, are covered by the third part of the definition of 'disability."').
109 Americans with Disabilities Act of 1990, 42 U.S.C. § 12201(C) (2009).
110 See Miller & Huvos, supra note 1o8, at 381-83.
i See EQUAL EMPLOYMENT OPPORTUNITY COMMISSION, COMPLIANCE MANUAL, CHAPTER 3:
EMPLOYEE BENEFITS (2000), available at http://www.eeoc.gov/policy/docs/benefits.html
(last visited Apr. 17, 2011).
112 Id.
113 See SECTION 902 DEFINITION OF THE TERM DISABILITY, supra note io8.
114 HIPAA directly addresses only "group health plans," defined as "an employee welfare
benefit plan to the extent that the plan provides medical care ... to employees or their
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information shall not be treated as a [pre-existing condition] in the
absence of a diagnosis of the condition related to such information.""is
This is important because under HIPAA, group health insurance plans
may exclude pre-existing conditions from coverage for up to twelve
months, provided that the participant received treatment, care, or
advice within six months prior to enrollment.116 Additionally, HIPAA
prohibits group health insurance plans from using "health status-
related factors," including genetic information,"17 to determine a
particular participant's eligibility"8 or to set differing premiums
among similarly situated individuals.119
As applied to certain "covered entities," HIPAA also limits the
circumstances under which "protected health information" may be
disclosed. Under the HIPAA Privacy Rule, a "covered entity" is defined
as "[a] health plan," "[a] health care clearinghouse, "[a] health care
provider who transmits any health information in electronic form in
connection with a transaction covered by this subchapter," or business
associates of another covered entity.120 Some vendors who supply
genetic tests through doctors and hospitals-such as Myriad Genetics
-are clearly at least business associates of covered entities.121
However, DTC genetic test vendors-such as 23andMe-do not fall
under definition of "covered entity," as most DTC genetic test vendors
are careful to characterize their services as non-diagnostic.122
dependents ... directly or through insurance, reimbursement, or otherwise." 29 U.S.C. §
186(a)(1) (2009).
1s Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. § 1181(b)(1)(B)
(2009).
n16 Id. § 1181(a) (2009).
117 Id. § 1182(a)(1)(F) (2009).
u8 Id. § 1182(a)(1) (2009).
119 Id. § 1182(b)(1) (2009).
120 45 C.F.R. §§ 160.102 & 160.103.
121 See Reimbursement Continued, http://www.myriadtests.com/index.php?page-id=314
(last visited Apr. 17, 2011).
122 See Lawrence Moore & Emily Sherlock, Federal Privacy Regulation and the Financially
Troubled DTC Genomics Company,Genomics Law Report,
http://www.genomicslawreport.com/index.php/2009/10/27/federal-privacy-regulation-
and-the-financially-troubled-dtc-genomics-company/ (Oct. 27, 2009) (last visited Apr. 17,
2011); See also Why Can't 23andMe Diagnose Me?, supra note 45; 45 C.F.R. § 160.103
(defining "health care" to include "Preventive, diagnostic, therapeutic, rehabilitative,
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If an entity is a "covered entity," it may not disclose "protected
health information" without the patient's authorization, except as
required or permitted by the HIPAA Privacy Rule.123 "Protected health
information" is defined as "individually identifiable health
information,"124 which the HHS has considered as including genetic
information even though it is not explicitly stated in the regulations.125
Permitted disclosures are those disclosures to the individual or those
disclosures for the purpose of "treatment, payment, or health care
operations."126 Significantly, "health care operations" are defined
broadly, and explicitly include insurance underwriting and risk
assessment.12 7
3. AMERICAN RECOVERY AND REINVESTMENT ACT
The ARRA-better known as the Stimulus Bill-required the HHS
and FTC to conduct a study on privacy, security, and breach-
notification requirements for "personal health record" ("PHR")
vendors and their related entities.128 It also required the FTC to issue
an interim health breach notification rule.129 In April 2009, the FTC
released its proposed health breach notification rule, and solicited
comments from the public.13o The proposed rule made no mention of
genetic information.
"Personal health records" are generally understood to be
"electronically accessible records of patient health care information
maintenance, or palliative care, and counseling, service, assessment, or procedure with
respect to the physical or mental condition, or functional status, of an individual or that
affects the structure or function of the body.").
12345 C.F.R. § 164.502.
12445 C.F.R. § 160.103.
125 Does the HIPAA Privacy Rule protect genetic information?,
http://www.hhs.gov/hipaafaq/about/354.html (last visited Apr. 17, 2011).
126 45 C.F.R.§ 164-502
12745 C.F.R. § 164-501
128 American Recover and Reinvestment Act of 2009, supra note 96.
129 Id.
130 Proposed Health Breach Notification Rule, 74 Fed. Reg. 17,914 (proposed Apr. 20,
2009) (to be codified at 16 C.F.R. pt. 318).
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that can be maintained by the patient. . . [and] may include medical
histories, prescription histories, and lab results that patients can give
to their providers."131 As one comment submitted by the Coalition for
Patient Privacy Rights observed, DTC genetic test vendors often
provide patients with online access to their test results, and could
therefore be deemed PHR vendors within the meaning of the health
breach notification rule.132 However, this comment was the only one of
129 comments received to suggest the inclusion of DTC genetic test
vendors, and the final interim health breach notification made no
mention of genetic information.133 While the HHS and FIC study
could ultimately conclude that PHR vendors should include DTC
genetic test vendors, the exclusion of DTC vendors from the FTC's
interim rule makes it unlikely.134
4. GENETIC INFORMATION NONDISCRIMINATION ACT
GINA required the HHS Secretary to modify the HIPAA Privacy
Rule such that "[g]enetic information shall be treated as health
information."35 GINA imposed a May 2009 deadline for the Secretary
to make these modifications.136 However, perhaps because of the
pending health breach notification rule discussed above, HHS did not
release its proposed rule implementing the modifications until
October 2009.137 While the proposed rule states that genetic
information has long been included under the Privacy Rule, the
proposed rule explicitly adds "genetic information" to the Privacy
Rule's definition of "protected health information."13 8
131 DANIEL R. LEVINSON, DEP'T OF HEALTH AND HUMAN SERVICES, OEI-o2-o6-oo270, STATE
MEDICAID AGENCIES' INITIATIVES ON HEALTH INFORMATION TECHNOLOGY AND HEALTH
INFORMATION EXCHANGE (Aug. 2007), at 2, available at
http://oig.hhs.gov/oei/reports/oei-o2-o6-OO270.pdf (last visited Apr. 17, 2011).
132 Katz, supra note 98, at 3.
133 Final Health Breach Notification Rule, supra note 99.
134 Moore & Sherlock, supra note 122.
'35 Genetic Information Nondiscrimination Act, 42 U.S.C. § 132od-9 (2009).
136 Genetic Information Nondiscrimination Act, 42 U.S.C. § 2oooff-10 (2009).
137 HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable
Health Information, supra note loo, at 51,700.
138 Id.
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The proposed rule goes on to define "genetic information" to
include an individual's genetic tests.139 "Genetic test" is defined as "an
analysis of human DNA, RNA, chromosomes, proteins, or metabolites,
that detects genotypes, mutations, or chromosomal changes."140
However, under GINA, "genetic test" excludes tests that are "directly
related to a manifested disease, disorder, or pathological condition."141
The proposed rule further clarifies that the term "manifested" applies
when non-genetic clinical symptoms can be observed and the disease
can be diagnosed on the basis of those non-genetic symptoms.142 Thus,
for example, although breast-ovarian carcinoma syndrome (severe
predisposition for breast or ovarian cancer) can be considered a
disease itself,143 GINA does not consider the disease "manifested" until
the patient can be diagnosed with breast cancer on the basis of non-
genetic clinical symptoms. Identical tests could be both included and
excluded under the definition of "genetic test" depending on the
clinical progression of the patient's disease. The rule cites the test for
Huntington's disease,144 which would be a "genetic test" until the
disease manifests clinical symptoms. At that point, the same test, used
merely to confirm the diagnosis, would not be a "genetic test."45
Also, while GINA and the accompanying HHS regulations do
clarify what genetic information is protected under HIPAA, GINA
does not affect the definition of "covered entities," nor is it clear
whether it significantly affects the information's permitted uses.146
Notably, this means that DTC genetic test vendors are still likely
outside the scope of the HIPAA privacy rule.147 Further, it is unclear to
139 Id.
140 Id.
141 Id. at 51,701.
142 Id. at 51,702.
143 See Katskee, supra note 14.
144 HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable
Health Information, supra note 100, at 51,702.
145 Id.
146 Moore & Sherlock, supra note 122.
147 Moore & Sherlock, supra note 122.
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what extent, if at all, GINA affects the ability of insurers to use genetic
information for underwriting or risk assessment purposes.148
5. PATIENT PROTECTION AND AFFORDABLE CARE ACT
PPACA extends and strengthens several HIPAA provisions
relevant to genetic privacy and nondiscrimination. First, it prohibits
all insurers from determining eligibility on the basis of "health status-
related factors" including genetic information.149 HIPAA's equivalent
provision applied only to "group health plans."15o Second, it prohibits
all insurers from setting differential premium rates except on the
basis of family structure, geography, actuarial value, tobacco use,
participation in a health promotion program, and age.'5' HIPAA
prohibited only differential premiums among "similarly situated
individuals," and applied only to "group health plans."152 And third,
PPACA prohibits all pre-existing condition exclusions.153 HIPAA
allowed certain pre-existing condition exclusions for up to twelve
months.154
Thus far, HHS has issued only a limited interim rule pursuant to
PPACA. The interim rule does not define "genetic information" or
explicitly specify how genetic information will be treated with respect
to "pre-existing conditions." However, the PPACA provision regarding
pre-existing conditions simply modifies its HIPAA counterpart, and
the interim rule generally adopts HIPAA's definition of "pre-existing
148 See HIPAA Administrative Simplification: Standards for Privacy of Individually
Identifiable Health Information, supra note 100, at 51,702-05.
149 Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, § 2705(a), 124
Stat. 156 (aoio) (effective Jan. 1, 2014) ("A group health plan and a health insurance
issuer offering group or individual health insurance coverage...").
1so Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. § 1182(a)(1)
(2009) ("...a group health plan, and a health insurance issuer offering group health
insurance coverage in connection with a group health plan...").
151 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 2701(a), 124
Stat. 155 (2010) (effective Jan. 1, 2014).
152 Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. § 1182(b)(1)
(2009).
153 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 2704(a), 124
Stat. 154 (2010) (effective Jan. 1, 2014).
'54 Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. § 1181(a) (2009).
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condition."5s Thus, it seems likely that the final rule will follow
HIPAA, which states that genetic information shall not be treated as a
pre-existing condition "in the absence of a diagnosis of the condition
related to such information."156 Similarly, although PPACA does not
explicitly define "genetic information," it seems likely that HHS will
ultimately adopt a similar definition to that in the rule promulgated
pursuant to GINA.57
B. STATE LAW
An increasing number of states have also passed laws pertaining to
genetic information. These laws generally fall within two categories:
(1) laws pertaining to genetic privacy, and (2) laws pertaining to
genetic nondiscrimination. As discussed below, however, the scope of
these state laws varies greatly.
1. STATE GENETIC PRIVACY LAWS
Only four states require that patients be given access to their
genetic information upon request. Delaware law states that "[a]n
individual promptly upon request, may inspect, request correction of
and obtain genetic information from the records of that individual."58
Meanwhile, twenty-nine states have passed laws that require
patient consent before various actions are taken with respect to
genetic information.159 Of these twenty-nine states, twelve have laws
requiring patient consent before a genetic test may be performed.160
'55 Requirements for Group Health Plans and Health Insurance Issuers Under the Patient
Protection and Affordable Care Act Relating to Preexisting Condition Exclusions, Lifetime
and Annual Limits, Rescissions, and Patient Protections, 75 Fed. Reg. 37,188 (proposed
June 28, 2010) (to be codified at 45 C.F.R. parts 144, 146, and 147).
is6 Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. § ii81(b)(i)(B)
(2009).
'57 See HIPAA Administrative Simplification: Standards for Privacy of Individually
Identifiable Health Information, supra note 1oo, at 51,700.
i8 DEL. CODE ANN.16, § 1223 (2009).
159 See Genetic Privacy Laws,
http://www.ncsl.org/IssuesResearch/Health/GeneticPrivacyLaws/tabid/14287/Default.as
px (last visited Apr. 17, 2011).
16o See id.
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For example, New York Civil Rights Law states, "No person shall
perform a genetic test on a biological sample taken from an individual
without the prior written informed consent of such individual..."161
Seven states also have laws requiring patient consent to access or
retain genetic information.162 For example, Minnesota law provides
that genetic information "may be used only for purposes to which the
individual has given written informed consent [and] may be stored
only for a period of time to which the individual has given written
informed consent." 6 3 Finally, twenty-seven states have laws that
require patient consent prior to the disclosure of genetic
information.164 For example, the New York Civil Rights Law provides
that genetic information "shall not be released to any person or
organization not specifically authorized by the individual subject of
the test."65
Five states have passed laws that actually define genetic
information as personal property.166 For example, Colorado law states:
"Genetic information is the unique property of the individual to whom
the information pertains."67 These laws, in particular, appear to
recognize the soul-like ability of genetic information to define one's
self.
Finally, nineteen states provide specific civil or criminal penalties
for violations of genetic privacy provisions.168 For example, Alaska law
creates a private right of action up to $5,000 for breaches of genetic
privacy resulting in no monetary gain for the violating party and up to
$100,ooo for breaches that do result in monetary gain.169
16, N.Y. Civ. RIGHTS LAW § 79-1(2) (2009).
162 See Genetic Privacy Law, supra note 159.
163 MINN. STAT. § 13-386 (2009).
164 See Genetic Privacy Law, supra note 159.
165 N.Y. civ. RIGHTS LAW § 79-L (2009).
166 See Genetic Privacy Law, supra note 159.
67COLO. REV. STAT. H 10-3-1104.6 & 10-3-1104.7 (2009).
iss See Genetic Privacy Law, supra note 159.
169 ALASKA STAT. § 18.13.020 (2009).
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2. STATE GENETIC NONDISCRIMINATION LAWS
All but four states have passed some form of law that prohibits
insurers from establishing eligibility rules on the basis of genetic
information.170 However, the laws vary in which types of insurers-
group or individual-are covered. For example, Alaska, Iowa, South
Dakota and Wyoming's antidiscrimination laws apply only to group
insurers; while Hawaii, Nebraska and West Virginia's
nondiscrimination laws apply only to individual insurers.x7' Laws from
the other thirty-nine states apply to both individual and group health
insurance companies.172 For example, Ohio prohibits insurers from
considering "any information obtained from genetic screening or
testing in processing an application for coverage for health care
services under an individual or group policy, contract, or agreement or
in determining insurability under such a policy, contract, or
agreement."173
Additionally, twenty-seven states have laws that prohibit insurers
from requiring genetic testing or requiring access to genetic
information.174 For example, the California Insurance Code states: "No
insurer shall require a test for the presence of a genetic characteristic
for the purpose of determining insurability other than for those
policies that are contingent on review or testing for other diseases or
medical conditions."7s
Finally, all but six states have laws that prohibit insurers from
using genetic information for risk selection or risk classification
purposes, at least under some circumstances.176 For example, New
Hampshire law states that health insurers shall not:
170 See Genetic Privacy Law, supra note 159.
171 Genetic Nondiscrimination in Health Insurance Laws, supra note lo8.
172 See Genetic Privacy Law, supra note 159.
73 OHIO REV. CODE § 1751.65 (2009).
174 See Genetic Privacy Law, supra note 159.
175 CAL. INS. CODE § 10148 (2009).
176 See Genetic Privacy Law, supra note 159.
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Consider in the determination of rates or any other
aspect of health insurance coverage or health care
benefits provided to an individual whether an
individual or a member of the individual's family has
undergone genetic testing or the results of the testing,
if undergone by the individual or a member of the
individual's family.177
Thus, while a large majority of states have passed at least some
form of law pertaining to either genetic privacy or genetic
nondiscrimination, their scopes vary greatly from state to state.
Further, these state laws follow similar approaches to federal law-
namely HIPAA, as modified by GINA-in that they seek to limit the
use and disclosure of "genetic information."
V. SHORTCOMINGS OF THE CURRENT LEGAL FRAMEWORK OF
GENETIC PRIVACY AND NONDISCRIMINATION
GINA was hailed as a triumph. Yet, even in the wake of GINA and
PPACA, the legal framework of genetic privacy and nondiscrimination
remains muddled, and some of the most pressing concerns remain
unresolved. First, DTC genetic test vendors remain outside the scope
of the HIPAA Privacy Rule. Second, because PPACA does not (yet)
define "genetic information," permitted uses of genetic information by
insurers remain inconsistent and unclear. And third, most
importantly, both federal and state genetic privacy and
nondiscrimination laws continue to ignore differences in the
predictive value of various genetic tests. While GINA does attempt to
address this issue in its definition of "genetic test" (which, as
discussed above, will also likely apply to PPACA), it fails to do so in a
statistically meaningful way. Assuming PPACA adopts GINA's
definition of "genetic information," it will likely prohibit most uses of
genetic test results by insurers. And in so doing, it will remove an
important incentive insurers had to cover the cost of genetic testing.
A. DIRECT-TO-CONSUMER GENETIC TEST VENDORS REMAIN OUTSIDE
THE SCOPE OF THE HIPAA PRIVACY RULE
As several commentators have observed, DTC genetic test vendors
likely remain outside the scope of the HIPAA Privacy Rule because
177 N.H. REV. STAT. §141-H:4 (2009).
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GINA did not modify the definition of "covered entity."178 The web
sites of the two major players in the DTC genetic testing industry-
23andMe and deCODE-make no mention of HIPAA.179 Of the DTC
genetic test vendors surveyed for this note, only Counsyl has
attempted to comply with the HIPAA Privacy Rule and GINA.18 o
However, Counsyl differs significantly from other DTC genetic test
vendors in two important ways. First, it explicitly characterizes its
services as diagnostic.18 1 Second, it offers its services both directly to
consumers and through doctors.182 Thus, Counsyl is almost certainly a
"covered entity" under HIPAA/GINA as either a "health care provider"
itself (because it offers diagnostic services) or a business associate of
other health care providers (because it offers its services through
doctors).
This continued exclusion of DTC genetic test vendors from scope
of the HIPAA Privacy Rules is problematic because of their increasing
popularity and the misleading advertising practices engaged in by
some vendors. A number of DTC genetic test vendors suggest that
their services are more protective of a customer's privacy because the
test is not ordered through a doctor and would not be part of one's
medical record. 83 Additionally, as deCODE's recent bankruptcy
178 Moore & Sherlock, supra note 122.
179 Privacy Statement, https://WWW.23andme.com/about/privacy/ (last visited Apr. 17,
2011); deCODE Genetics, http://www.decode.com/company/terms.php#privacy (last
visited Apr. 17, 2011).
1so Your Privacy, https://www.counsyl.com/about/privacy/ (last visited Apr. 17, 2011).
181 Early Testing Allows Prevention, https://www.counsyl.com/learn/prevent-genetic-
disease/ (last visited Apr. 17, 2011).
isa2The Universal Genetic Test, https://www.counsyl.com/learn/universal-genetic-test/
(last visited Apr. 17, 2011) ("Get your kit from your local doctor's office.").
183 Kathy Hudson et al., ASHG Statement on Direct-to-Consumer Genetic Testing in the
United States, 81 AM. J. HuMAN GENETICS 635, 636 (2007); See, e.g., Tera Eerkes, The
Scary Truth About Your Genetic Information (Sept. 4, 2oo8),
http://www.genedream.net/wordpress/?p=12 (last visited Apr. 17, 2011) ("Don't let
someone take your genetic info (even if it's anonymized) and sell it to other people,
EVER...Don't let someone take your genetic info and use it for research they won't happily
tell you about...Don't let someone take your genetic information and use it for anything
unless they promise that you can have it back whenever you want it. I can't name names,
but these three things are big No-Nos, and they are also things that several personal
genetic testing companies are currently doing. Obviously, QTrait doesn't do this."); See
also Brandon Keim, Genetic Protections Skimp on Privacy, Says Gene Tester, wired
Science, http://www.wired.com/wiredscience/2008/05/genetic-protect/ (May 23, 2008,
08:13 EDT) (last visited Apr. 17, 2011).
demonstrates, the exclusion of DTC genetic test vendors from HIPAA
makes it unclear what control a customer would have over his or her
genetic information if a DTC genetic vendor goes bankrupt.184
B. PERMITTED USES OF GENETIC INFORMATION BY INSURERS REMAIN
INCONSISTENT AND UNCLEAR
As discussed above, federal protections against genetic
discrimination by insurers have historically been limited. HIPAA did
prohibit excluding pre-existing genetic disorders from coverage after
twelve months, but pre-existing conditions were defined narrowly and
the exclusion was permitted for twelve months.185 Although GINA
clarified "genetic information," it did little to affect its permitted uses.
Further, HIPAA applied only to group insurers and did not protect
those seeking coverage in the individual health insurance market.
Beginning in 2014, PPACA will indeed prohibit all insurers from
determining eligibility on the basis of genetic information and,
generally, from setting differential premiums. 86 PPACA will also
prohibit all pre-existing condition exclusions. 87 However, PPACA
does not define "genetic information." And although PPACA will likely
adopt GINA's definition of the term, it is therefore still somewhat
unclear exactly what information insurers may consider in
determining eligibility. For example, PPACA specifically allows
insurers to set differential premiums on the basis of tobacco use.188
Yet, studies have shown that genetic factors may predispose some
individuals to addiction to tobacco.189 If a policy holder both uses
tobacco and possesses a gene that predisposes him or her to
continued addiction, it may thus be somewhat unclear whether the
184 Dan Vorhaus, deCODE Declares. Now What?, Genomics Law Report,
http://www.genomicslawreport.com/index.php/2009/11/17/decode-declares-now-what/
(Nov. 17, 2009) (last visited Apr. 17, 2011).
185 Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. § 1181(a) (2009).
186 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 2701(a), 124
Stat. 155 (2010) (effective Jan. 1, 2014).
187 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 2704(a), 124
Stat. 154 (2010) (effective Jan. 1, 2014).
188 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, §
2701(a)(1)(A)(iv), 124 Stat. 155 (2010) (effective Jan. 1, 2014).
189 Kalivas, supra note 91.
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insurer could set a higher premium on the basis of his or her tobacco
use.
Further, PPACA does not address whether severe genetic
predisposition for a particular disease constitutes a "pre-existing
condition." Thus, it is unclear whether insurers must cover
prophylactic care for an individual who, for example, tested positive
for a mutation to BRCA1 or BRCA2 prior to enrolling in the plan.
Accordingly, at least until HHS promulgates further rules (and even
then, until 2014), genetic privacy and nondiscrimination protections
remain largely a function of state law.
At the state level, the scope of protection varies widely. Alabama,
for example, prohibits only the use of genetic test results revealing a
predisposition for cancer. 190 Other states prohibit such a broad scope
of genetic information uses that their prohibitions are impracticable.
For example, New Hampshire prohibits the consideration of genetic
test results in "any ... aspect of health insurance coverage...."191
However, a "genetic test" is defined as "a test, examination, or
analysis, which is generally accepted in the scientific and medical
communities for the purpose of identifying the presence, absence, or
alteration of any gene or chromosome."192 Because genetic disorders
are, by definition, caused by genetic abnormalities, this definition of
"genetic test" includes diagnostic as well as predictive tests. It is
difficult to imagine that insurers would never be able to consider,
under any circumstances, whether a policy holder currently manifests
cancer. Further, this is not traditionally what is meant by genetic
discrimination.193
Moreover, such heavy-handed genetic privacy and
nondiscrimination laws can conflict with other medically sound
objectives. Minnesota's genetic privacy law requires patient consent
prior to the use, storage, or dissemination of genetic information.194
190 ALA. CODE § 27-53-2 (2009).
191 N.H. REv. STAT. § 141-H:4 (2009).
192 N.H. REV. STAT. § 141-H:1 (2009).
193 Michael S. Yesley, Protecting Genetic Difference, 13 BERKELEY TECH. L.J. 653, 662
(1998) ("It is important to note that whether genetic information is defined narrowly or
broadly in the laws barring genetic discrimination, the term generally does not include
information about expressed, or existing, genetic disorders. The quintessential feature of
genetic discrimination is the use of genetic information about an asymptomatic person. If
the disorder related to a genetic characteristic has occurred, discrimination based on the
disorder may be unfair but is not customarily considered 'genetic discrimination.').
194 MINN. STAT. § 13-386 (2009).
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Like New Hampshire discussed above, Minnesota defines "genetic
information" extremely broadly:
(a) "Genetic information" means information about an
identifiable individual derived from the presence,
absence, alteration, or mutation of a gene, or the
presence or absence of a specific DNA or RNA marker,
which has been obtained from an analysis of:
(1) the individual's biological information or specimen;
or
(2) the biological information or specimen of a person
to whom the individual is related.
(b) "Genetic information" also means medical or
biological information collected from an individual
about a particular genetic condition that is or might be
used to provide medical care to that individual or the
individual's family members.195
However, as the plaintiffs' claims in Bearder, et. al. v. State of
Minnesota96 demonstrate, this law's broad and heavy-handed
protection is potentially inconsistent with another Minnesota statute,
which requires newborn screening for certain inherited diseases,
including PKU.197 Newborn screening for PKU has long been
considered justified given the severe consequences of the disease and
the accuracy of its test.198  Thus, heavy-handed genetic
privacy/nondiscrimination statutes and over-broad definitions of
genetic information are not only impracticable for insurers, but could
also interfere with legitimate and scientifically sound medical
objectives.
195 Id.
196 788 N.W.2d 144, 144 (Minn. Ct. App. 2010) (Plaintiffs claim "that respondents'
collection, retention, use, or dissemination of appellant-children's blood in conjunction
with a state-mandated newborn screening program violated their ... rights [under the
state's genetic privacy act, among other things]").
197 MIN. STAT. § 144.125 (2009).
1s See Screening for phenylketonuria (PKU): U.S. Preventive Service,
http://www.guideline.gov/content.aspx?id= 12270 (last visited Apr. 17, 2011) ("The
USPSTF recommends screening for phenylketonuria (PKU) in newborns.").
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C. GENETIC PRIVACY AND NONDISCRIMINATION STATUTES Do NOT
ADDRESS DIFFERENCES IN PREDICTIVE VALUE
At the heart of these shortcomings is a failure of genetic
nondiscrimination laws to address the differences in statistical
predictive values of different genetic tests. It may be true that all
genetic discrimination raises at least some concerns. For example,
allowing insurers to set higher premiums for those with greater risk
for disease on the basis of accurate genetic information could
potentially increase societal costs through decreased use of
preventative medicine and early treatment if such individuals are
unable to afford adequate insurance. However, the greatest threat of
genetic discrimination centers on the risk that individuals could be
categorized on the basis of an inaccurate assessment of their risk for
the future manifestation of clinically symptomatic disease.199
Several commentators have observed that, to the extent genetic
information can accurately predict a particular individual's risk for
disease, consideration of genetic information by insurers is natural
and even desirable. Time Magazine contributor Michael Kinsley
states:
The very appealing notion that genetic discrimination
is unfair looks especially odd in the context of
insurance. The idea of insurance is to protect against
the unexpected or unlikely. Forbidding insurers to take
predictable risks into account when choosing whom to
insure and how much to charge is asking them to
behave irrationally and make bets they are sure to lose.
Not insuring people who are likely to get cancer, or
charging them more, isn't evil. It's rational behavior. Of
course, we outlaw a lot of behavior that would be
rational if it weren't against the law. But the skeptics
who say this is a step on the way to universal health
care actually understate the case. To truly apply the
appealing principle that people should not be
discriminated against because of their genes would be a
leveling experiment, like something out of Stalinist
Russia or China's Cultural Revolution.200
199 See Yesley, supra note 193, at 662.
200 Michael Kinsley, Inherited Properties, TIME, May 19, 2oo8, at 56.
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Similarly, Eric Rakowski, a professor at the U.C. Berkley School of
Law, argues that parents who choose to give birth to "genetically
disadvantaged" children in spite of undesirable test results should
incur greater liability "because they could not fairly push the cost of
their choices off on other members of the insurance pool."201 Others
have observed that our society generally accepts placing increased
costs and burdens on those who suffer from obesity, a condition that
is, at least in part, hereditary.202
Thus, what is often lost from the discussion on genetic
discrimination is that genetic discrimination itself is not necessarily
what is to be avoided; it is unfair genetic discrimination. As Kinsley
observes, setting insurance premiums on the basis of risk is clearly not
new or undesirable. The fear of genetic discrimination should
therefore largely center on the (probably justified) fear that genetic
tests may be inaccurate in their reflection of risk.
In that regard, genetic tests do present a more complicated
statistical problem than conventional medical tests. A conventional
medical test generally contains only one level of statistical risk
analysis: how likely the observed trait (i.e., cholesterol level, blood
pressure, etc.) is to cause the associated disease. The accuracy of the
test in measuring the observed trait is generally high, or at least well
understood. Genetic tests introduce a second, and often overlooked,
layer of statistical analysis to the problem. Not only must one
determine the degree of correlation between the observed genetic
mutation and the disease, but one must also determine whether the
test results accurately reflect the genotype of the patient.
GINA does recognize that different genetic tests have different
"predictive power."203 However, "predictive value" has a particular
statistical meaning that GINA's modifications to the HIPAA Privacy
Rule do not reflect. In determining whether an observed genotype
actually exists in the patient, statisticians refer to "positive predictive
value" ("PPV") and "negative predictive value" ("NPV").204 PPV, the
percentage of positive test results that are true positives, is defined as
follows:
201 Eric Rakowski, Who Should Pay for Bad Genes?, go CAL. L. REV. 1345, 1345 (2002).
202 See e.g., Sayward Byrd, Civil Rights and the 'Twinkie" Tax: The 9oo-Pound Gorilla in
the War on Obesity, 65 LA. L. REV. 303 (2005).
203 HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable
Health Information, supra note 100, at 51,702.
204 Interview with Jason Hsu, Professor of Statistics, The Ohio State University, in
Columbus, Ohio (Feb. 6, 2010).
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(S ens itivity) (Pr evalence)
(Sensitivity) (Prevalence) + (1 - specif icity) (1 - prevalence)
NPV, the percentage of negative test results that are true negatives, is
defined as follows:
(Specif icity)(1 - prevalence)
(Specif icity) (1.- prevalence) + (Prevalence) (1- sensitivity)
"Sensitivity" is the proportion of people with the target condition
who have a positive test result, and "specificity" is the proportion of
people without the target condition who have a negative test result.205
"Prevalence" refers to the percentage of the population affected with a
particular disease at a given time.206 Significantly, prevalence is
relevant in both the PPV and NPV equations. Even if a given genetic
test has extremely high sensitivity and specificity, the test may have
poor positive predictive value (i.e., the test will produce a high
percentage of false positives) if the prevalence of the particular
genotype is extremely low.
For example, Counsyl claims 99.9% sensitivity and specificity.207
One of the diseases tested, Achromatopsia, occurs in approximately 1
in 33,000 Americans.208 While 99.9 % sensitivity and specificity
would seem excellent, the prevalence of 1 in 33,000 leads to a PPV of
only approximately 0.0294. This means that 33 out of 34 positive test
results for Achromatopsia will be false positives.
While the PPV and NPV formulas clearly apply regardless of
whether a test or disease is genetic or not, genetic disorders are often
extremely rare compared to non-genetic disorders, and additional
testing to confirm a genetic diagnosis is often not immediately
205 Glossary of EBM Terms, http://ktclearinghouse.ca/cebm/glossary (last visited Apr. 12,
2011).
206 Merriam Webster's Online Medical Dictionary, http://www.merriam-
webster.com/medical/prevalence (last visited Apr. 17, 2011).
207 Prescribed at Yale Fertility Center, https://www.counsyl.com/learn/reliable/ (last
visited Apr. 17, 2011).
20s Achromatopsia, https://www.counsyl.com/diseases/achromatopsia/ (last visited Apr.
17, 2011).
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available. Because low prevalence leads to poor PPVs and high false
positive rates, false positives are particularly problematic for genetic
tests. Although GINA acknowledges differing "predictive power," it
fails to take into account the challenge presented by varying PPVs of
genetic testing in a statistically meaningful way.
Similarly, even aside from the risk of inaccurate genotyping,
possessing a particular genetic variant associated with a disease does
not necessarily lead to the manifestation of clinical symptoms. As the
HHS interpretation of GINA recognizes: "In some cases, an individual
may have a genetic variant for a disease and yet never develop the
disease. In other cases, the presence of a genetic variant means that
the individual will eventually develop the disease."2o9 While this
observation is a step in the right direction compared to previous
federal and state approaches, it still fails to articulate precisely the
particular concern over genetic discrimination in the insurance
context.
As with all risk factors for non-genetic disease, the concern over
genetic discrimination in the insurance context should center on
whether the risk can be accurately characterized, not whether the risk
is loo% or less.210 GINA's classification of genetic tests on the basis of
their temporal relation to the manifestation of clinical symptoms thus
mischaracterizes the concern.2 1 ' Moreover, GINA does not even
accomplish its "ioo% versus less than loo% distinction" with
precision. One example cited-the test for Huntington's disease-is
considered a "genetic test" (and thus treated as possessing suspect
predictive power) when it is administered prior to the onset of clinical
symptoms. Yet, an individual with the tested-for genetic variant will
invariably develop the disease later in life.212
209 HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable
Health Information, supra note loo, at 51,702.
210 See Kinsley, supra note 200.
211 The manifested/un-manifested distinction makes significantly more sense in the
employment context. There, one might be concerned if an employer refuses to hire an
individual who has a predisposition for-but does not yet possess symptoms of-a
condition that would prevent the individual from performing his or her job. See Chai
Feldblum, Commissioner, Equal Emp. Opp. Comm'n, Remarks at Cornell University,
Implementing the Genetic Information Nondiscrimination Act: A Public Policy Forum
(Feb. 1, 2011).
212 HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable
Health Information, supraz note 100, at 51,702.
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This is not to suggest that a more effective classification system for
tests necessarily exists. Quite the opposite is true. It is extremely
challenging to classify the accuracy of a genetic test's analysis of
patient risk on the basis of the type of test. The possession of some
genetic variants-such as those leading to PKU or Huntington's
disease-predicts future manifestations of clinical symptoms with a
high degree of statistical certainty. Other genetic variants, on the other
hand, do not. Even mutations to BRCA1 and BRCA2, which strongly
correlate with breast and ovarian cancer, do not definitively predict
the eventual development of breast cancer because cancer is a
complex interaction of many genes and environmental factors.213 Not
surprisingly, the correlations between the mutations for which some
DTC vendors test and the future manifestation of clinical symptoms
are largely unknown.214 It is also worth noting that test accuracy is not
necessarily a function of the complexity of the genetic mechanism
involved. For example, MammaPrint, which tests a seventy-gene
group, has been shown to predict the recurrence of breast cancer with
a sufficiently high degree of statistical confidence to be clinically
useful, as evidenced by its FDA approval.215
Just as it is difficult to characterize the accuracy of a genetic test
on the basis of the type of gene(s) it tests, the type of technology used
also does not necessarily indicate the results' reliability. MammaPrint,
23andMe, and Counsyl all use similar microarray technology.216 Yet,
MammaPrint has been approved by the FDA, while little evidence
exists to validate the reliability of 23andMe.
This is perhaps best explained by the empirical methods that
scientists use to search for genes associated with complex diseases. As
discussed above, most genetic disorders are caused by complex
interactions between numerous genes and environmental factors. 217
213 See BRCA1 and BRCA2: Cancer Risk and Genetic Testing,
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (last visited Apr. 17, 2011).
214 U.S. FED. TRADE COMM'N, AT-HOME GENETIC TESTS: A HEALTHY DOSE OF SKEPTICISM
MAY BE THE BEST PRESCRIPTION (July 2oo6), at 2-3, available at
http://www.ftc.gov/bcp/edu/pubs/consumer/health/heao2.pdf (last visited Apr. 17,2011).
215 U.S. Food & Drug Admin., FDA Clears Breast Cancer Specific Molecular Prognostic
Test, supra note 25.
216 Our Service: Genotyping Technology, supra note 43; Breast Cancer Test Leverages
Advances Made by Human Genome Project,
http://www.agendia.com/pages/microarray technology/41.php (last visited Apr. 17,
2o11).
217 SNPs: Variations on a Theme, supra note 12.
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To determine which genes are associated with a particular disease,
scientists often use microarrays to detect differences in gene
expression levels between normal and diseased tissue.s Microarrays
can perform this analysis on thousands of genes at one time.219
However, this technique has been observed to produce inconsistent
results, with "gene signatures" for the same disease that often do not
overlap between independent studies.22o Without independent
validation of a particular "gene signature," it is difficult to confirm
correlations observed in any particular study.
In contrast to the "empirical" methods employed by MammaPrint
and 23andMe to identify the relevant genes, Counsyl tests only for
diseases caused by (or primarily caused by) well-known mutations to
single genes. Thus, it is potentially more reliable than other
microarray-based genetic tests because less empirical methods are
used to identify the relevant genes. However, because Counsyl has not
released any of its data, its claims of accuracy are impossible to
validate.221
To some extent, PPACA reduces this classification problem with
its sweeping prohibition of differential premiums. However, when this
prohibition becomes effective in 2014, it will also remove much of the
incentive insurers currently have to cover the cost of genetic testing.
Although genetic testing may, in the long run, reduce overall health
care costs, most genetic testing would do so only indirectly.222 Without
direct cost-reduction through either more accurate risk assessment or
preventative measures, insurers will lack an incentive to cover the
often substantial cost of genetic testing. Also, it is worth noting that
while PPACA will require insurers to cover "preventive services,"223 it
essentially defines "preventive services" as those with a U.S.
218 Microarrays Factsheet, http ://www.ncbi.nlm.nih.gov/About/primer/microarrays.html
(last visited Apr. 17, 2011).
219 Id.
220 JaSon Hsu, et al., Statistically Designing Microarrays and Microarray Experiments to
Enhance Sensitivity and Specificity, 8 BRIEFINGS IN BIOINFORMATICS 22, 22 (2007).
221 Pollack, supra note 33.
222 See e.g., Genetic Basis of Cancer Syndromes, supra note 15; Kasparian, supra note 8o;
Evans & Relling, supra note 52.
223 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 13o2(b)(1)(I),
124 Stat. 164 (2010) (effective Jan. 1, 2014).
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Preventive Services Task Force ("USPSTF") grade of A or B.224 The
USPSTF has not addressed most genetic testing procedures; it even
recommends BRCA1/BRCA2 testing, which is relatively well
understood compared to other genetic tests, only for those with a
history of breast cancer. 2 2 5 Thus, it is unlikely that the USPSTF will
recommend-and accordingly, that insurers will be required to cover-
other, less well understood genetic tests.
VI. RECOMMENDATIONS FOR FUTURE APPROACHES
To GENETIC PRIVACY AND NONDISCRIMINATION
Future legislative and regulatory efforts to address genetic privacy
and nondiscrimination should at least include DTC genetic test
vendors within their scope. However, for legislative and regulatory
schemes to truly address the complex problem of genetic privacy and
nondiscrimination effectively, they must ultimately move beyond the
traditional HIPAA approach, which simply limits the disclosure and
use of certain categories of information. Future efforts should focus on
providing privacy and nondiscrimination protections that reflect the
different statistical positive and negative predictive values of
particular tests. Such a regulatory scheme would require that genetic
test vendors actually disclose statistical data and would require
greater statistical expertise within the governmental agencies tasked
with oversight. Because the FDA already possesses such expertise
through its current regulation of drugs and certain medical
diagnostics, future genetic privacy and nondiscrimination schemes
should therefore take into account whether the test is FDA-approved.
Finally, additional protections for genetic information that seek to
address its "soul-like" quality should remain primarily a matter of
state law.
A. DIRECT-TO-CONSUMER GENETIC TEST VENDORS SHOULD BE
SUBJECT TO HEALTH PRIVACY LAWS
Of the shortcomings of the current legal framework for genetic
privacy and nondiscrimination, perhaps the simplest to rectify is the
224 Patient Protection and Affordable Care Act 2010, Pub. L. No. 111-148, § 4104(a), 124
Stat. 557 (2010) (effective Jan. 1, 2011).
225 Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer
Susceptibility: Recommendation Statement, available at
http://www.ahrq.gov/clinic/uspstfo5/brcagen/breagenrs.pdf (last visited Apr. 17. 2011).
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exclusion of DTC genetic test vendors from the HIPAA Privacy Rule.
For example, the definition of "health care" could be amended to read
as follows:
Preventive, diagnostic, genotyping, phenotyping,
genetic sequencing, therapeutic, rehabilitative,
maintenance, or palliative care, and counseling,
service, assessment, or procedure with respect to the
physical or mental condition, or functional status, of an
individual or that affects the structure or function of
the body...226
Such language would bring DTC genetic test vendors-who offer
genotyping, phenotyping, and genetic sequencing services-under
HIPAA's definition of "health care provider," and thus under its
definition of "covered entity."227 This would close what has been a
major gap in genetic privacy legislation,228 and would also more
accurately reflect consumers' understanding of their DTC genetic test
results.229 Even DTC genetic test vendors themselves appear to agree
that patients often misinterpret their test results as medically
significant information, as evidenced by their advice to seek genetic
counseling.23o
226 Cf 45 C.F.R. § 160.103 (proposed amendments emphasized).
227 See 45 C.F.R. §§ 160.102 & 160.103.
228 Moore & Sherlock, supra note 122.
229 Shane Green and Mike Spear, Getting Personal with DNA: From Genome to Me-Ome,
11 VIRTUAL MENTOR 714, 717-18 (2009) (The article details how Mike, a 23andMe,
deCODE, and SNPedia customer, changed his behavior after receiving his genetic test
results. Mike sought the advice of his doctor and committed to regular eye testing after
tests uncovered a supposed increased risk for age-related macular degeneration and statin-
related SAEs.).
230 Genetic Counselors Facilitate Your Practice,
http://www.navigenics.com/visitor/for-physicians/our-services/genetic-counseling/
(last visited Apr. 17, 2011); FAQ, http://www.decodeme.com/faq ("We also offer free
genetic counseling through our network of certified genetic counselors.") (last visited Apr.
17, 2011); Genetic Testing for Carrier Status, Disease Risk and Drug Response,
https://www.23andme.com/health/carrier/ ("23andMe health reports include where to
look for more information, support group contacts, and links to genetic counseling
resources.") (last visited Apr. 17, 2011).
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B. GENETIC PRIVACY AND NONDISCRIMINATION LEGISLATIVE AND
REGULATORY SCHEMES SHOULD REFLECT THE DIFFERING STATISTICAL
CONFIDENCE LEVELS OF DIFFERENT TESTS
The more complex legislative and regulatory problem is the great
variation in statistical confidence levels between particular tests. As
discussed above, the multiple layers of statistical analysis make it
difficult to separate genetic tests into clean categories that lend
themselves to similar statistical reliability. While the entities currently
tasked with oversight-the non-FDA portions of HHS and the FTC-
lack the statistical expertise to evaluate tests on a test-by-test basis,
the FDA has long performed this function with respect to drugs,
medical devices and procedures.
Therefore, future privacy legislation and regulation should take
FDA approval status into account in determining the level of privacy
and nondiscrimination protection afforded to the patient. Even the
FDA's 501(k) Premarket Notification Program, under which the
majority of genetic tests are approved,231 requireS an applicant to
demonstrate that its test is safe and effective, even if only as compared
to similar existing FDA-approved tests. 2 32 Allowing insurers to
consider genetic information produced by FDA-approved tests, while
prohibiting insurers from considering information produced by non-
FDA-approved tests, would afford policy holders some level of
confidence that insurers would base eligibility and premium decisions
only on accurate genetic information and simultaneously maintain a
significant incentive for insurers to cover the tests' costs. This would
also disincentivize use of the "in-house" exemption by test
manufacturers, which the FDA recognizes has been problematic in the
area of complex genetic tests, 2 33 because insurers would likely stop
231 CAROL A. HOLLAND, Ass'N. FOR MOLECULAR PATHOLOGY, FDA-CLEARED/APPROVED
MOLECULAR DIAGNOSTIC TESTS, available at
http://www.amp.org/FDATable/FDATable.doc (last visited Apr .17, 2011).
232 See generally Food & Drug Admin., Overview of IVD Regulation,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssist
ance/ucml23682.htm (last visited Apr. 17, 2011).
233 FOOD & DRUG ADMIN., IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAYS (July 2007),
at 7-8, available at
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidance
Documents/UCMo71455.pdf (last visited Apr. 17, 2011).
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reimbursing policy-holders for the genetic tests whose results they
could not consider.234
Notably, FDA approval under 501(k) also generally involves
reporting sensitivity, specificity, and positive and negative predictive
values.235 Because patients often overlook positive and negative
predictive values in evaluating the reliability of a test, particularly
when presented with apparently excellent sensitivity and specificity
data, this requirement could well lead to more rational patient
responses to test results. While certainly not every patient would read
or understand the information, at least such information would be
available. Currently, such information is either only available through
calculation or is not available at all.
C. ADDITIONAL PROTECTIONS FOR GENETIC INFORMATION SHOULD
REMAIN IN THE REALM OF STATE LAW
A number of commentators have observed that elevating genetic
information to a "soul-like" expression of one's personal identity is
problematic, at least within the context of federal law.236 Nonetheless,
for some, genetic information is deeply personal in a way that extends
beyond other health information.237 For these individuals, genes are as
much intrinsic to their sense of self as their face, their physical
features, and their voice.238 How (or should) this "soul-like" quality of
DNA influence the legal framework of genetic privacy and
nondiscrimination? I suggest that it should be addressed primarily at
the state level.
In many ways, fundamental privacy rights (as opposed to the
primarily practical ones discussed above) resemble property rights in
that they involve an inherent right to exclude others from making use
234 Cf. Covered by Insurance, https://www.counsyl.com/Iearn/free-with-insurance/ (last
visited Apr. 17, 2011).
235 FOOD & DRUG ADMIN., STATISTICAL GUIDANCE ON REPORTING RESULTS FROM STUDIES
EVALUATING DIAGNOSTIC TESTS (Mar. 2007), at 7-8, available at
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/Guidance
Documents/ucmo71287.pdf (last visited Apr. 17, 2011).
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of a particular thing.239 Thus, to invoke DNA as a "soul-like" entity
would be to treat it, in a sense, as personal property.240 However, just
as society's conception of property rights almost certainly varies
greatly from state to state,2 4 1 not all individuals view their DNA as
equivalent to their soul.
Given that the "soul-like" quality of DNA is probably not
universally accepted across the country, it therefore seems unlikely
and unwise to incorporate such consideration into federal law.
Instead, the limited scope of state law appears the more appropriate
venue. 2 42 Moreover, treatment of genetic information as essentially
personal property should not be incorporated into privacy and
nondiscrimination law, but would instead be more properly addressed
under property law. This has, of course, already happened to an
extent.243 However, as the federal legal landscape for genetic privacy
and nondiscrimination clears, states considering additional
protections for genetic information should understand that some of
the desire for such increased protection likely stems not from
concerns about discrimination, but rather from a sense that, at least
for some individuals, genetic information is an important part of their
self-identity.
VII. CONCLUSION
The increasing complexity of genetic tests has rendered the
traditional HIPAA-based approach to genetic privacy and
nondiscrimination ineffective. First, the direct-to-consumer genetic
testing phenomenon has left a large gap in the scope of genetic privacy
239 See id., at 186-87.
240 See e.g., CoLO. REV. STAT. §§ 1o-3-1104.6(1)(a) & 1o-3-1104.7(1)(a) (2009) (defining
genetic information as personal property).
241 See Hon. Jeffrey S. Sutton, Why Teach - And Why Study - State Constitutional Law,
34 OKLA. CiTY U.L. REv. 165, 174 ("Does anyone doubt that...the Montana Supreme Court
might look at property rights differently from other States or the United States Supreme
Court?").
242 See id., at 173 ("In some settings, the challenge of imposing a constitutional solution on
the whole country at once will increase the likelihood that federal constitutional law will be
underenforced or that a 'federalism discount' will be applied to the right. State courts face
no such problem in construing their own constitutions.").
243 E.g., ALAsKA STAT. § 18.13.olo(A)(2); COLO. REV'. STAT. § 10-3-11o4.7(1)(A); FLA STAT. §
760.4o(2)(A); GA. CODE ANN. § 33-54-1(1); LA REV. STAT. ANN. § 22:1023(E).
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protections. HIPAA's Privacy Rule should explicitly cover such
entities.
Second, the fear that inaccurate genetic test results will lead to
unfair discrimination by health insurers is justified, but blunt, heavy-
handed approaches to defining protected "genetic information" do not
reflect wide variation in the statistical reliability of particular genetic
tests. Because such differences are difficult, if not impossible, to
categorize, a new approach to genetic privacy and nondiscrimination
should emerge. Incorporating the FDA approach to efficacy that
already exists for other medical diagnostics into genetic privacy and
nondiscrimination schemes would likely address these concerns in a
meaningful way.
Finally, many individuals perceive that they have an ownership
interest in their DNA because DNA, in a way, exemplifies their self-
identity. However, the protection of this perceived interest does not fit
well within federal privacy law. Instead, any such additional
protections for genetic information should fall within a regime of
property law and remain in control of the states.
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